the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email .

Share this:
Brief Title Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse/ Refractory Multiple Myeloma
Official Title A Phase I, Open Label Study To Evaluate The Safety, Pharmacokinetic, Pharmacodynamic And Clinical Activity Of Pf-06863135, A B-cell Maturation Antigen (Bcma)-cd3 Bispecific Antibody, In Patients With Relapsed/Refractory Advanced Multiple Myeloma (mm)
Principal Investigator Jakubowiak, Andrzej
Brief Summary To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
Gender All
Ages 18 Years
Enrollment 80
Accepts Healthy Volunteers No
Lead Sponsor PfizerIndustry
Study Design
Study Phase Phase 1
Study Type Interventional
Contact Name
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Multiple Myeloma
Detail for Health Professional (on
More clinical trials by this PI